---
title: "CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295800631.md"
datetime: "2026-08-13T12:42:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295800631.md)
  - [en](https://longbridge.com/en/news/295800631.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295800631.md)
generator: "portal-rs"
---

# CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EBIT: As of FY2026 Q2, the actual value is USD -5.729 M.

### Financial Overview: Second Quarter and First Half 2026

#### Cash and Working Capital

As of June 30, 2026, Cingulate Inc. reported $28.4 million in cash and cash equivalents, an increase from $11.0 million as of December 31, 2025. This increase was primarily driven by $12.0 million raised from a private placement and $19.0 million from At-the-Market Agreement and Purchase Agreement, partially offset by $12.8 million in cash used for operations. The company’s working capital was approximately $21.6 million as of June 30, 2026, an increase of $19.9 million compared to December 31, 2025.

#### Research and Development (R&D) Expenses

For the three months ended June 30, 2026, R&D expenses were $1.5 million, a 44.9% decrease from $2.7 million for the same period in 2025. For the six months ended June 30, 2026, R&D expenses were $3.7 million, a 25.4% decrease from $5.0 million in the first half of 2025.

#### Selling, General and Administrative (SG&A) Expenses

SG&A expenses for the three months ended June 30, 2026, were $3.9 million, an increase of 101.5% compared to $1.9 million for the same period in 2025. For the six months ended June 30, 2026, SG&A expenses rose to $9.7 million, an increase of 181.7% from $3.4 million in the first half of 2025.

#### Operating Loss

Operating loss for the three months ended June 30, 2026, was - $5.4 million, compared to - $4.6 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, the operating loss was - $13.3 million, an increase from - $8.4 million for the six months ended June 30, 2025.

#### Net Loss

Net loss for the three months ended June 30, 2026, was - $5.9 million, compared to - $5.0 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, net loss was - $15.2 million, compared to - $8.8 million for the six months ended June 30, 2025.

#### Other Financial Data (Balance Sheet as of June 30, 2026)

-   Total assets: $33.1 million.
-   Total liabilities: $9.6 million.
-   Accumulated deficit: - $147.6 million.
-   Total stockholders’ equity: $23.5 million.

#### Outlook / Guidance

Cingulate Inc. anticipates that its current cash and cash equivalents of $28.4 million will be sufficient to fund operations into mid-2027. This funding is expected to cover costs for completing requested CMC work, seeking regulatory approval for CTx-1301, and continuing the build-out of commercial readiness capabilities. The company remains committed to resubmitting the NDA for CTx-1301 as promptly as practicable following the completion of CMC work.

### Related Stocks

- [CINGW.US](https://longbridge.com/en/quote/CINGW.US.md)

## Related News & Research

- [Ecosuntek adds Q3 KPI update to 2026 corporate events calendar](https://longbridge.com/en/news/298712114.md)
- [SpyCloud 2026 Identity Threat Report Finds Non-Human Identities Are Now the Leading Path into the Enterprise](https://longbridge.com/en/news/298456224.md)
- [HPS/PayMedix Named a 2026 Best and Brightest Company to Work For](https://longbridge.com/en/news/298358823.md)
- [Annaly Capital declares Q3 2026 dividend of $0.75 per share](https://longbridge.com/en/news/298499808.md)
- [Essex Property Trust declares Q3 2026 dividend of R$ 0.89 per unit](https://longbridge.com/en/news/298322539.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**